Printer Friendly

ALPHA 1 BIOMEDICALS, INC. SHARES NOW TRADE IN NASDAQ NATIONAL MARKET

 BETHESDA, Md., June 17 /PRNewswire/ -- The common stock and Class C warrants of Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) will begin trading on June 21, 1993 in the NASDAQ National Market System, Vincent F. Simmon, Ph.D, president and chief executive officer announced today. Alpha 1's common stock trading symbol is ALBM and the Class C warrant symbol is ALBML.
 Dr. Simmon noted that Alpha 1's entry into the NASDAQ National Market provides brokers and others with immediate access to the best bid and asked prices and other information about the company's shares throughout the trading day. Those prices are available over more than 190,000 electronic terminals in broker's offices throughout the United States and the free world. Trading data are also distributed widely through wire services for dissemination by newspapers and radio and television stations.
 "We are delighted with the increased market visibility that presence on NASDAQ will bring. Many of our shareholders in the United States and abroad will now be able to see daily quotes of our shares in their local newspapers" said Dr. Simmon.
 Alpha 1 Biomedicals, Inc. is engaged in the development of pharmaceutical products for the treatment of chronic viral diseases, immune disorders and cancer. The company's lead drug, Thymosin alpha 1, is currently in U.S. clinical trials for the treatment of chronic hepatitis B, chronic hepatitis C and AIDS.
 -0- 6/17/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 Biomedicals, Inc., 301-564-4400, or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals, Inc./
 (ALBM)


CO: Alpha 1 Biomedicals ST: Maryland IN: MTC SU:

LD-TM -- NY097 -- 3328 06/17/93 17:53 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 1993
Words:279
Previous Article:UNIVAR CORP. ANNOUNCES IMPROVED FIRST-QUARTER EARNINGS
Next Article:NIELSEN ANNOUNCES TECHNOLOGY PARTNERSHIP WITH EDS
Topics:


Related Articles
ALPHA 1 BIOMEDICALS, INC. COMPLETES
/FOLLOWING IS A REPEAT OF A RELEASE MOVED YESTERDAY/
ALPHA 1 BIOMEDICALS, INC. APPOINTS SUZANNE K. BECKNER AS DIRECTOR OF DEVELOPMENT
ALPHA 1 BIOMEDICALS ANNOUNCES INITIATION OF ARBITRATION PROCEEDINGS WITH LICENSEE
ICN BIOMEDICALS ISSUES $62 MILLION IN PREFERRED STOCK
ALPHA 1 ANNOUNCES STOCK SALE
COMMON STOCKS OF ICN PHARMACEUTICALS, THREE OPERATING UNITS, TOP MAJOR STOCK MARKET INDICES IN 1993
ALPHA 1 ANNOUNCES COMPLETION OF STOCK SALE
SCICLONE ACQUIRES STAKE IN ALPHA 1
SCICLONE'S BOARD APPROVES STOCK BUYBACK

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters